2025
A flexible Bayesian g-formula for causal survival analyses with time-dependent confounding
Chen X, Hu L, Li F. A flexible Bayesian g-formula for causal survival analyses with time-dependent confounding. Lifetime Data Analysis 2025, 31: 394-421. PMID: 40227517, DOI: 10.1007/s10985-025-09652-3.Peer-Reviewed Original ResearchConceptsG-formulaBalance scoresHealth system electronic health recordDiscrete survival dataTime-to-event outcomesPosterior sampling algorithmParametric g-formulaElectronic health recordsBayesian additive regression treesTime-varying treatmentsHypothetical intervention scenariosAdditive regression treesLongitudinal observational studyGeneral classModel misspecificationHealth recordsEmpirical performanceSampling algorithmObservational studySurvival dataIntervention scenariosScoresTreatment strategiesMisspecificationCausality analysis
2024
Four targets: an enhanced framework for guiding causal inference from observational data
Lu H, Li F, Lesko C, Fink D, Rudolph K, Harhay M, Rentsch C, Fiellin D, Gonsalves G. Four targets: an enhanced framework for guiding causal inference from observational data. International Journal Of Epidemiology 2024, 54: dyaf003. PMID: 39868475, PMCID: PMC11769716, DOI: 10.1093/ije/dyaf003.Peer-Reviewed Original ResearchRationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis
Barsotti G, Luciano R, Kumar A, Meliambro K, Kakade V, Tokita J, Naik A, Fu J, Peck E, Pell J, Reghuvaran A, Tanvir E, Patel P, Zhang W, Li F, Moeckel G, Perincheri S, Cantley L, Moledina D, Wilson F, He J, Menon M. Rationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis. Kidney International Reports 2024, 9: 1354-1368. PMID: 38707807, PMCID: PMC11068976, DOI: 10.1016/j.ekir.2024.02.006.Peer-Reviewed Original ResearchMinimal change diseaseRandomized controlled trialsSafety of metforminDouble-blindPodocyte injuryAdjunctive therapyPlacebo-controlled randomized controlled trialsPhase III studyPhase II trialPrimary glomerular diseaseFocal segmental glomerulosclerosisEffect of metforminPhase IIPlacebo-controlledPreclinical dataNovel urineChange diseaseTissue markersRandomized trialsSegmental glomerulosclerosisGlomerular diseaseMechanistic biomarkersObservational studyFSGSInexpensive agent
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply